Experimentally induced mammalian models of glaucoma by Ishikawa, Makoto et al.




Experimentally induced mammalian models of
glaucoma
Makoto Ishikawa
Akita Graduate University School of Medicine
Takeshi Yoshitomi
Akita Graduate University School of Medicine
Charles F. Zorumski
Washington University School of Medicine in St. Louis
Yukitoshi Izumi
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Ishikawa, Makoto; Yoshitomi, Takeshi; Zorumski, Charles F.; and Izumi, Yukitoshi, ,"Experimentally induced mammalian models of
glaucoma." BioMed Research International.2015,. 1-12. (2015).
http://digitalcommons.wustl.edu/open_access_pubs/4180
Review Article
Experimentally Induced Mammalian Models of Glaucoma
Makoto Ishikawa,1 Takeshi Yoshitomi,1 Charles F. Zorumski,2,3 and Yukitoshi Izumi2,3
1Department of Ophthalmology, Akita Graduate University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
2Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA
3The Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA
Correspondence should be addressed to Makoto Ishikawa; mako@med.akita-u.ac.jp
Received 25 September 2014; Accepted 1 December 2014
Academic Editor: Oreste Gualillo
Copyright © 2015 Makoto Ishikawa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
A wide variety of animal models have been used to study glaucoma. Although these models provide valuable information about
the disease, there is still no ideal model for studying glaucoma due to its complex pathogenesis. Animal models for glaucoma are
pivotal for clarifying glaucoma etiology and for developing novel therapeutic strategies to halt disease progression. In this review
paper, we summarize some of the major findings obtained in various glaucoma models and examine the strengths and limitations
of these models.
1. Introduction
Glaucoma is characterized by progressive and accelerated loss
of retinal ganglion cells (RGCs) and their axons [1]. Although
the pathogenesis of glaucoma is not fully understood, it is
believed that increased intraocular pressure (IOP) is a major
contributor even in normal tension glaucoma [2]. In this
context, a wide variety of animalmodels have been developed
to study the effect of elevated IOP on the optic nerve and the
RGC degeneration.
In general, animal glaucoma models are classified into
two categories: natural-occurring models and induced mod-
els. A variety of natural-occurring glaucoma models have
been described in different animal species including dog
(beagle) [3], albino New Zealand rabbit [4], and DBA/2J
mice [5–7]. It has been considered that the disturbance or
obstruction of aqueous outflow could be the cause of IOP
elevation, which induces a loss of RGCs and excavation
of the optic nerve in these models [8]. Because naturally
occurring glaucomamodels are poor in controlling onset and
pathological course of the disease, induced glaucoma models
have been developed with the aim to create proper conditions
for controlled experiments. The earliest models of induced
glaucoma were developed in monkeys [9], and IOP elevation
was induced by intraocular 𝛼-chymotrypsin injections [10].
Thereafter, multiple in vivo glaucoma models have been
developed using laser photocoagulation of the perilimbal
region [11], autologous fixed red blood cell (RBC) injection
[12] or microbead injection into the anterior chamber [9],
cauterization of episcleral veins [13], or hypertonic saline
injection into the episcleral veins [14, 15]. Recently, in vitro
[16] and ex vivo glaucomamodels [17] have been developed to
improve the accuracy and repeatability of experimental con-
ditions and to examine pathological mechanisms especially
in the acute phase of the IOP elevation. Hydrostatic pressure
is applied to cells cultured on a rigid substrate or to isolated
retinal tissues in vitro and ex vivo. More recently, transgenic
mouse glaucomamodels, which were genetically modified by
the introduction of a foreignDNAsequence into amouse egg,
have emerged [18].
In this paper, we present a summary of experimentally
induced mammalian glaucoma models that have been devel-
oped and used for the recent study of the different types of
glaucoma and discuss limitations and potential use of each
model.
2. In Vivo Glaucoma Models
2.1. Laser Photocoagulation of the Perilimbal Region. Multiple
studies have used laser photocoagulation which induced
sustained IOP elevation in monkeys [11], mice [19, 20],
rats [21], and rabbits [22–24]. These models were primarily
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developed to study retinal IOP-related posterior segment
damage. The IOP elevations in eyes treated with laser photo-
coagulation are thought to result from increased resistance of
outflow pathways such as angle closure, trabecular scarring,
and obliteration of Schlemm’s canal [11]. Gaasterland and
Kupfer (1974) [11] applied repeated, circumferential argon
laser photocoagulation to the trabecular meshwork in both
eyes of each of the five Rhesus monkeys and induced a
sustained IOP elevation in seven out of ten eyes by a marked
reduction in outflow. The IOP range was between 24 and
50mmHg after the 4th treatment and remained elevated by
30 days. The main outcome analyzed to determine whether
this experimental ocular hypertension can induce a glaucoma
was indicated by the observed development of cupping of the
optic disc and by the selective loss of retinal ganglion cells in
histopathologic specimens. This model became the standard
for laser-induced glaucoma in monkeys [25–29].
The advantage of the primate model is that the monkeys
have eyes with similar anatomical characteristics to humans.
Although monkeys are excellent animal models for studying
human disease, there are several limitations to use mon-
keys, including ethical and economic factors [30, 31]. Laser
photocoagulation requires expensive ophthalmic equipment
and highly specialized techniques. Laser photocoagulation
sometimes induces the inflammation of the anterior chamber
and irreversible mydriasis [28].
In contrast to primate models, there are several advan-
tages of using rodents (mice, rats, and rabbits) in glaucoma
research. Rodents are inexpensive and easy to house and
handle, their eyes are easy to obtain, and the sample number
for studies can be large [32]. Aihara et al. (2003) [19]
applied argon laser photocoagulation to the corneal limbus
in Black Swiss mice after flattening the anterior chamber
by aspiration of aqueous humor and successfully induced
persistent elevation of IOP for at least 6 weeks in mouse eyes.
The flattening of the anterior chamber appears to bring the
trabecular meshwork into closer proximity to limbal areas
targeted with the laser and may be useful in enhancing the
effect of photocoagulation to obstruct the anterior chamber
angle [19]. Significant increases in mean IOP during 4 to 12
weeks were detected in treated eyes [19]. Average IOPs in
laser-treated eyes (IOPtx) versus contralateral control eyes
(IOPc) during the first 4 weeks and during the entire 12-week
study period were 23.4 ± 5.1mmHg versus 16.3 ± 2.3mmHg
and 20.1 ± 3.5mmHg versus 16.2 ± 2.4mmHg, respectively
[19]. Average IOPtx was significantly higher than the average
IOPc during both periods (𝑃 < 0.001) [19]. A treatment
response was considered to be a success if either the mean
of IOP measurements collected during the first 4 weeks was
increased by 30% or more or the mean of all measurements
collected during the 12-week study period was increased by
30% or more [19]. During the first 4 weeks, 14 (64%) of 22
eyes had an IOP increase of more than 30% [19]. During
the entire 12-week study, 7 (37%) of 19 eyes maintained
an IOP increase of greater than 30% [19]. The success rate
of IOP elevation after a single procedure is relatively high
compared with other glaucoma models. Histologic analysis
at the end of the 12-week study showed that the angle was
completely closed by the laser photocoagulation treatment
[20]. Disadvantages of this method include ocular inflam-
mation induced by laser treatment, flattening of the anterior
chamber, and variability of IOPmagnitude and duration [19].
In addition, the IOP elevationwas not sustained in the treated
eyes, slowly declining to baseline by 8 weeks after treatment
[19]. In optic nerve cross sections examined by electron
microscopy 300 𝜇m posterior to the globe [20], mean axon
density and total number of axons in the laser treated eyes
were significantly decreased compared with the control eyes.
Other studies applying argon laser photocoagulation to
the episcleral and limbal veins in C57BL/6 mice [33, 34]
induced IOP elevations lasting for weeks after treatment, with
decline to baseline levels approximately 8 weeks after treat-
ment [34]. After laser treatment, mean IOP was increased
in the treated eyes from the control mean of 13 ± 1.8mmHg
to 20.0 ± 2.8mmHg at 4 weeks in C57BL/6 mice [33]. Peak
IOP was 32 ± 2.5mmHg in the experimental group. RGC
loss was 16.9% ± 7.8% at 2 weeks (𝑃 < 0.05) and 22.4% ±
7.5% at 4 weeks (𝑃 < 0.05) after laser photocoagulation [33].
TUNEL staining showed that there were marked increases
in the number of apoptotic nuclei in the ganglion cell
layer in the treated eyes [33]. Laser photocoagulation of
limbal and episcleral veins also induces transient ocular
hypertension in albino CD-1 mice [35]. In albino CD-1 mice,
the IOPs measured in operative eyes (27.6 ± 2.6mmHg)
were significantly elevated above those measured in control
eyes (12.3 ± 1.0mmHg) 4 hours after laser treatment and
remained elevated at the second postoperative day (operative
27.1 ± 1.8mmHg versus control 13.4 ± 0.3mmHg) [35]. IOPs
measured in laser-treated eyes declined to baseline and were
similar to IOPs in control eyes by 1 week (operative 15.4 ±
1.3mmHg versus 12.4 ± 0.6mmHg). Overall, the elevation
of IOP is transient in these laser models, and the level of cell
loss is modest.
Similar tomice, rats are easy tomaintain in the laboratory,
and they can be used in large numbers [21, 36–40]. Laser
photocoagulation has been applied to the trabecular mesh-
work alone [41] or the trabecular meshwork and episcleral
veins [42] in rats, and the induced IOP elevation results
in subsequent glaucomatous damage, including RGC loss
[41, 42]. Levkovitch-Verbin et al. [42] induced experimental
glaucoma unilaterally in Wistar rats, using a diode laser with
wavelength of 532 nm aimed only at the trabecular meshwork
(trabecular group) or at episcleral veins (combination treat-
ment group) through the external limbus. IOP was increased
in all eyes to higher than the normal mean IOP of 19.4 ±
2.1mmHg after the laser treatment [42]. Peak IOPwas 34.0 ±
5.7mmHg in the trabecular group and 49.0 ± 6.1mmHg
in the combination group [42]. Mean IOP after 6 weeks
was 22.0 ± 1.8mmHg in glaucomatous eyes in the trabecular
group compared with 25.5 ± 2.9mmHg in the combination
group [42]. IOP in the glaucomatous eyeswas typically higher
than in the control eyes for at least 3 weeks [42]. In the
combination group, RGC loss was 16.1% ± 14.4% at 1 week
(𝑃 < 0.01), 59.7% ± 25.7% at 6 weeks (𝑃 < 0.001), and
70.9% ± 23.6% at 9 weeks (𝑃 < 0.001) [42]. The trabecular
group had mean axonal loss of 19.1% ± 14.0% at 3 weeks
(𝑃 < 0.004) and 24.3% ± 20.2% at 6 weeks (𝑃 < 0.001) [42].
Laser treatment led to closure of intertrabecular spaces and
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the major outflow channel [42]. The retina and choroid were
normal by ophthalmoscopy at all times after treatment. Light
microscopic examination showed only loss of RGCs and their
nerve fibers [42]. Although continuous IOP elevation over
longer periods is ideal, 3 weeks of elevated IOP induces
substantial RGC loss and axonal damage of the optic nerve,
making the model attractive for most investigations [42].
There are several limitations to using laser-induced ocular
hypertension in rats. First, differences in pigmentation of the
trabecular meshwork markedly change the effects of laser
photocoagulation to increase IOP. Second, repeated laser
treatments induce ocular inflammation and corneal opacity
[43].
2.2. Red Blood Cell or Microbead Injections into the Anterior
Chamber. To circumvent the limitations and disadvantages
of laser techniques, microbeads were injected into the ante-
rior chamber to induce ocular hypertension in primates [9],
pigs [30], mice [44], rats [45], and rabbits [46]. An alternative
to microbead injection uses injection of autologous fixed red
blood cells (RBCs) into the anterior chamber [12, 47]. Ele-
vations in IOP observed in autologous RBCs- or microbead-
injected eyes are thought to result from inhibition of aqueous
outflow.
Experimental primate models of chronic IOP elevation
were developed by Quigley and Addicks (1980) using autolo-
gous fixed RBCs (ghost cells) [12, 47]. Direct obstruction of
the trabecular meshwork by ghost cells as well as swelling
of trabecular cells following phagocytosis of cellular debris
was observed by electron microscopy. The model has the
advantages of producing IOP elevation easily (mean IOP,
24mmHg to 73mmHg) and without associated intraocular
inflammation [12]. However, IOP elevations lasted from 2 to
42 days, and the extensive filling of the anterior chamber
with ghost cells resulted in poor visibility of the optic disk
[12]. Ghost cells are degenerating red blood cells with-
out hemoglobin content. Subsequently, Weber and Zelenak
(2001) [48] reported that multiple injections of sterile latex
microspheres (2–4 × 105 sterile beads per injection) into
the primate anterior chamber are simple and cost effective
for inducing chronic IOP elevation [48]. In the treated eyes
withmultiple injections of latexmicrospheres, mean IOPwas
17.8mmHg to 36.7mmHg, and peak IOP was 23mmHg to
65mmHg [48]. Different levels and durations of elevated IOP
can be obtained by altering the frequency and number of
microspheres injected [47].This approach has the advantages
of producing IOP elevations while preserving visibility of
the optic disc, which is necessary for assessment of glau-
coma development [48]. Fluorescent polystyrene microbead
injection into the anterior chamber of C57BL/6 mice results
in chronic IOP elevation (4.6 ± 0.6mmHg above control
IOP) lasting for at least 3 weeks following a single injection
[49]. Cone et al. (2012) [50] maintained the IOP elevation
by a combination of polystyrene bead injection followed
by viscoelastic solution injection into the mouse anterior
chamber. The disadvantages of the mouse model include the
relatively small size of the globe, which makes it hard to
manipulate.
IOP elevations induced by microbeads have also been
described in rat models [40]. In Wistar rats injected with
microbeads, IOP elevation persists for two weeks and results
in reduced density of the optic nerves [40, 51]. Wistar rats
receiving weekly injections of hyaluronic acid show IOP
elevation that persists for at least 10 weeks [51].
Taken together, microbead injection models offer a rel-
atively easy technique without special equipment, and the
IOP elevation can bemodulatedwith subsequent injections of
microbeads or viscous materials. The principal disadvantage
is that microbeads can be difficult to retain in the ante-
rior chamber angle after injection. To address these issues,
Samsel et al. (2011) [52] developed a technique for induc-
tion of ocular hypertension using paramagnetic microbeads.
Magnet is used to direct microbead to the anterior chamber
angle. These beads have the advantage that they can be
directed to the anterior chamber angle in the rodent eye
to optimize occlusion of the trabecular meshwork. In this
case, the paramagnetic microbeads could be directed to the
iridocorneal angle using a handheld magnet [52].
2.3. Episcleral Vein Obstruction. Shareef et al. (1995) [15]
developed an episcleral vein cauterizationmodel of glaucoma
in rat. This method is less invasive than laser photocoagula-
tion and induces no complications in the anterior chamber
[53]. Because of its efficacy and accessibility, the majority
of the structural and functional studies in experimental
glaucoma have used this method [13]. IOP elevations in this
model are thought to involve increased outflow resistance
[54].
Mouse glaucoma models induced by episcleral vein cau-
terization exhibit significantly elevated IOP (28 ± 1.5mmHg)
for up to 4 weeks and loss of RGCs [54]. Photocoagulation of
episcleral and limbal veins induces a doubling of IOP lasting
for 4 hours in albino CD1 mice [55, 56]. Complications of
episcleral vein cautery in mice include thermal damage to
sclera, intraocular inflammation, and ocular surface damage.
To compare the effects of IOP elevation on ganglion
cell size and death, Vecino and Sharma (2013) [57] used
three experimental glaucoma models in rats: (i) injections of
latex microspheres into the anterior chamber, (ii) injections
of microspheres and hydroxypropylmethylcellulose into the
anterior chamber, and (iii) cauterization of three episcleral
veins. IOP elevation induced by episcleral vein coagulation
was more stable and constant for at least 24 weeks as com-
pared with the other two experimental glaucoma methods.
Similar results were observed when the three methods were
compared in rats [58] and pigs [44].
Morrison et al. [14] have suggested, however, that patho-
physiology in the episcleral vein cautery model differs from
the other two ocular hypertension models, and the pattern of
RGC death might be different in this model. While axonal
degeneration of RGCs is the predominant finding in the
other IOP elevation models, episcleral vein cautery appears
to produce general RGC loss, indicating the possibility that
factors other than IOP elevation might contribute to RGC
death in episcleral vein cautery models.
4 BioMed Research International
Table 1: Experimentally induced in vivomammalian glaucoma models.
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IOP: IOP measurement, cupping: assessment of optic disc cupping, HR: histological assessment of retinal nerve fibers and optic discs, HI: histological
assessment of the iridocorneal angles, OF: outflow facility, ERG: electroretinography.
2.4. Episcleral Vein Saline Injection. Kipfer-Kauer et al. (2010)
[59] have succeeded in inducing chronic IOP elevation in
C57BL/6 mice by injection of 1.5M hypertonic saline into a
limbal vein. The hypertonic saline injection group revealed
a mean IOP of 9.99 ± 3.3mmHg versus 7.42 ± 2.2mmHg
in the contralateral control eye. Peak IOP in the hypertonic
saline injection group was 15.6mmHg versus 11.6mmHg in
the control group. Episcleral vein saline injection causes an
increase in the resistance of aqueous outflow channels. To
develop chronically elevated IOP in rats, episcleral veins were
injected with hypertonic saline in Brown Norway rats, and
IOP elevations (7 to 28mmHg above control pressure) were
sustained after 4 weeks [14]. The anterior chamber angles
showed the formation of the peripheral anterior synechia.
Electron micrographs of eyes from this model showed glau-
comatous damage of RGC axons [14].
The disadvantage of these latter models is the relative dif-
ficulty of the induction technique. Insertion of a microneedle
into the rat episcleral vein requires considerable training and
experience. An additional disadvantage is that the duration
of IOP elevation is relatively short and sequential hypertonic
saline injections are needed to produce longer lasting IOP
changes [60].
Taken together, a wide variety of in vivo animal models
have been developed to study the effect of elevated IOP on the
optic nerve and RGC degeneration. However, the duration of
IOP elevation in these models is transient without sequential
treatments. In addition, precise control over IOP elevation
is difficult, and the timing of induction and progression of
glaucoma are usually unpredictable. Table 1 is the summa-
rization of characteristics of the experimentally induced in
vivomammalian glaucoma models.
3. In Vitro Glaucoma Models
While in vivo animal models are necessary to show that
a phenomenon occurs in living organisms, experiments in
live animals typically involve undefined and uncontrollable
factors [43].Therefore, in vitro experimental systems are use-
ful for producing highly controlled experimental conditions
to manipulate specific variables contributing to degenerative
changes [43]. Recently, in vitro glaucomamodels that use cells
cultured on a rigid substrate have been described [16, 61–72].
Thesemodels have usedRGCs, optic nerve head astrocytes, or
other types of retinal cells and sometimes have been equipped
with pressure loading systems.
The application of hydrostatic pressure induces remark-
able changes including enhancement of RGC apoptosis [64,
66], alterations in astrocyte structure [57], cellmigration [63],
elastin synthesis [68], and production of neural cell adhesion
molecules [69]. Obazawa et al. (2004) [73] developed a
cell culture system for manipulating hydrostatic pressure to
examine the expression of optineurin and myocilin genes
in trabecular meshwork cells under normal and hyperbaric





Figure 1: System used for hydrostatic pressure experiments. The
culture chamber was filled with medium.The height of the medium
reservoir was adjusted to maintain the pressure in the culture. For
gas exchange, the medium was circulated by a peristaltic pump, and
the pressure was monitored with the pressure gauge. This figure is
themodification of Figure 1 of Lei et al. [61] and Figure 1 ofObazawa
et al. [73].
conditions (Figure 1). Kashiwagi et al. (2004) [74] examined
the survival and morphology of isolated RGCs subjected to
centrifugal force loading using the unique device (Figure 2).
The device includes a rotating vessel installed within a large
incubator (model CPO2-1800; Hirasawa, Tokyo, Japan), a
power supply unit, a control unit, and a cooling motor
for removing heat generated by the motor installed outside
the device. The rotor spins at 1 to 30 rotations per minute
(rpm), with a rotation accuracy of 0.01 rpm. The equation
for calculating centrifugal force (𝐹) is 𝐹 (mmHg) ≒ 1.12𝑟×
(rpm/1000) × 750, where 𝑟 is radial distance (in millimeters).
Recently, Yu et al. (2011) [75] developed a more conve-
nient and simple pressure system using T75 culture flasks. An
air mixture of 95% air and 5% CO
2
is pumped into the flasks
to obtain the desired pressure.
In vitro models are also useful for investigating the role
of apoptotic mechanism in RGCs. RGC death induced by
IOP elevation involves caspase activation as demonstrated
using experimental rat models of glaucoma [76]. In vitro
studies provide strong evidence that apoptosis of retinal
neurons induced by different stimuli shares a common
caspase cascade [66, 77], which can be inhibited using specific
caspase inhibitors [78]. Additionally, Tezel and Yang (2004)
[79] applied TNF-𝛼 or hypoxia to primary cultures of rat
RGCs for up to 48 hours and found that inhibition of caspases
cannot block RGC death if the mitochondrial membrane
potential is lost and cell death mediators (cytochrome c and
apoptosis-inducing factor) are released.
Identification of precise cellularmechanisms in glaucoma
requires isolation and primary culture of the RGCs. It has
been known that in vitro experiments using primary cultures
of RGCs are difficult to perform, mainly because of the
limited yield and the typically postmitotic features of these
Culture chamber Culture chamber
Figure 2: Schema of the centrifugal force loading device.The device
is composed of two culture chambers and amotor unit for providing
centrifugal force and rotor vessels. The isolated cells are situated
at the bottom of the culture dish to become perpendicular to the
direction of the centrifugal force and gravity vectors corresponding
to a rotation speed. This figure is the modification of Figure 1 of
Kashiwagi et al. [74].
neurons [80]. Therefore, early postnatal tissues are used in
an attempt to optimize cell number and survival in culture.
However, there are differences in cell responses between
postnatal and adult cells that can limit interpretation of
experimental results. In addition, it is difficult to examine
interactions between RGCs and other types of cells such as
retinal glia in specific mechanisms.
4. Ex Vivo Glaucoma Models
We recently developed a new ex vivo experimental model for
acute glaucoma that involves incubating rat retinal segments
under hydrostatic pressure at the bottom of a deep cylinder
[17] (Figure 3). Acute high pressures can induce retinal
ischemia clinically and in in vivo glaucoma models [81, 82].
The ex vivo hydrostatic pressuremodel excludes the influence
of ischemia and can thus allow examination of the direct
effects of hydrostatic pressure on the otherwise intact retina,
including changes in gene and protein expression [83, 84].
While the ex vivo system produces reliable results, we
note several limitations. Survival factors for retinal neurons
supplied from the blood stream or axonal transport are
eliminated in ex vivo preparations, and the incubation period
is limited by the duration in which the tissue can be kept
alive.The advantages of this model include a higher degree of
control over experimental variables and better preservation
of neuron-neuron and neuron-glial interactions that are
possible in dissociated cell preparations.
Of interest in this ex vivomodel is the finding that axonal
swelling in RGCs is induced in a pressure-dependentmanner.
In the central nervous system, activation of neuronal gluta-
mate receptors induces swelling of cell bodies and dendrites
[85–88] and also produces Na+-dependent blebs in acutely
isolated hippocampal neurons [89]. This swelling is caused
by the influx of Na+ and Ca2+ and the passive redistribution
of chloride and water across neuronal membranes [88–90].
Similar events occurring in axons could contribute to the
findings observed in the ex vivo glaucoma model. Because













Figure 3: Outline of the experiment using ex vivo glaucoma model.
Eyecups preparations were sunken to the bottom of a glass cylinder
with different heights. Each cylinder was filled with incubation





. Hydrostatic pressure at the bottom of the cylinder was
calculated to be 10mmHg and 75mmHg when a CSF was added
to a height of 13.5 cm and 101.2 cm, respectively. This figure is the
modification of Figure 1 of Ishikawa et al. [17].
administration of glutamate receptor antagonists attenuated
the axonal swelling, we hypothesize that glutamate-mediated
changes contribute to axonal swelling under hyperbaric
conditions.
To determine whether increased pressure triggers release
of ATP, Reigada et al. (2008) [91] loaded air or nitrogen
pressure to ex vivo bovine eyecups [91]. One milliliter of
buffer solution was added to the bottom of each eyecup
and the lid was sealed. Air or nitrogen was injected from
a syringe until the pressure reading by digital manometry
reached the desired level. When appropriate precautions
were taken, pressure levels remained constant throughout
the experiment. ATP released from retinal cells diffuses into
the vitreous humor. Vitreous humor from each eyecup was
collected, andATP concentrationswere determined. Elevated
pressure led to an increase in extracellular ATP. This excess
extracellular ATP may serve as a link between increased
pressure and RGC death in acute glaucoma, suggesting a
possible role for ATP in neuronal damage accompanying
increased intracranial pressure.
Table 2 is the summarization of characteristics of the
experimentally induced in vitro and ex vivo mammalian
glaucoma models.
5. Genetically Modified Mouse
Glaucoma Models
There are numerous mouse models in which glaucoma-like
pathology occurs as a result of genetic mutations [43, 92]. A
main advantage of these glaucoma models is higher repro-
ducibility of responses following IOP elevations compared to
surgically induced models [42]. Because there is significant
conservation in mouse and human genomes, the generation
ofmicewith specificmutations identified in human glaucoma
can be useful for understanding pathogenesis [43]. We
briefly review studies that have utilized genetically modified
mouse models to examine the roles of different genes in the
glaucoma pathogenesis.
5.1. GLAST and EAAC-1. Normal tension glaucoma (NTG)
is a condition in which clinical features are largely identical
to those seen in primary open angle glaucoma (POAG)
except for the relatively low IOP (<22mmHg). The patho-
physiology of RGC degeneration and optic nerve damage in
NTG remains unclear. To explore possible pathways of RGC
degeneration, genetically modified mice with normal IOP
have been used as models of NTG. Harada et al. [18] showed
that mice with deficient expression of the glutamate trans-
porters, GLAST or EAAC-1, demonstrate spontaneous RGC
death and optic nerve degeneration without elevated IOP. In
GLAST-deficient mice, administration of a glutamate recep-
tor antagonist prevented RGC loss, indicating that GLAST
helps to prevent excitotoxic retinal damage. Additionally,
GLASThelps tomaintain levels of the antioxidant glutathione
in Mu¨ller cells by transporting glutamate, the substrate for
glutathione synthesis, into the cells. Taken together, it appears
that GLAST deficiency leads to RGC degeneration by both
excitotoxic and oxidative stress mechanisms.
GLAST deficient mice were also used to investigate
ASK1 deficiency on RGC death [93]. Apoptosis signal-
regulating kinase 1 (ASK1) is a mitogen-activated protein
kinase (MAPK) that plays an important role in stress-induced
RGC apoptosis. Loss of ASK1 had no effects on the pro-
duction of glutathione or malondialdehyde in the retina or
on IOP. Tumor-necrosis-factor (TNF) induced activation of
p38MAPK and production of inducible nitric oxide synthase
were also suppressed in ASK1-deficient Mu¨ller glial cells and
RGCs, suggesting that ASK1 activation is involved in NTG.
5.2. CYP1B1. CYP1B1 is a gene implicated in congenital glau-
coma and codes the enzyme, cytochrome P450, family 1,
subfamily b, polypeptide 1 [94, 95].The role thatCYP1B1 plays
in the pathophysiology of glaucoma and the development
of anterior chamber anomalies is not known. Nonetheless,
CYP1B1-deficient mice exhibit abnormalities in their aque-
ous drainage system that are similar to those reported in
BioMed Research International 7
Table 2: Experimentally induced in vitro and ex vivomammalian glaucoma models.
Species Main papers Pressure(mmHg)
Duration
(hours) Main outcomes measured
In vitro glaucoma models




Centrifugation model Rat Kashiwagi et al. (2004) [74] 16, 28, 33 24, 48 Expressional changes in mRNAin RGC and retinal glia
Ex vivo glaucoma models
Hydro pressure model Rat Ishikawa et al. (2010) [17] 10, 25, 50, 75 24
Histology of the retinal nerve
fiber, Glutamine synthetase
activity
Gas pressure model Bovine Reigada et al. (2008) [91] 20–100 0.5 Retinal ATP release
human angle-closure glaucoma patients [96]. In contrast,
other studies using CYP1B1-null mice revealed no evidence
of IOP elevation [97]. Although CYP1B1 knockout mice do
not develop elevated IOP, they have abnormalities in their
aqueous drainage system, small or absent Schlemm’s canal,
defects in trabecular meshwork, and peripheral anterior
synechia of the iris [97]. A mouse model with mutations
in both CYP1B1 and Tyr was also developed and revealed
that Tyr mutation modifies the phenotype associated with
inheritance of mutant orthologs of CYP1B1 and Foxc1, both
of which have been shown to be involved in human angle-
closure glaucoma [96, 97].
5.3. Alpha-1 Subunit of Collagen Type 1. More recently, a
transgenic mouse model of POAG has emerged. This mouse
model has a targeted mutation in the gene for the alpha-1
subunit of collagen type 1 and demonstrates progressive loss
of RGC axons induced by IOP elevation [98]. Organization of
the drainage structures seems normal in this model.
5.4. Myocilin. The myocilin gene (Myoc) encodes a secreted
glycoprotein. Tyr437His mutation in Myoc leads to severe
glaucoma in humans [99], and the mouse Tyr423His muta-
tion corresponds to this human mutation [100]. Tyr423His
Myoc mice demonstrate progressive degenerative changes
in the peripheral RGC layer and optic nerve, with normal
organization of aqueous drainage structures [101]. It has been
suggested that mice expressing mutated mouse or human
Myoc in the trabecular meshwork have characteristics of
POAG [101, 102]. By contrast, expression of themutatedMyoc
allele (Tyr423His) specifically in the iridocorneal angle does
not lead to IOP elevation and does not produce degener-
ative changes in the retina [103]. These differences might
be explained by differences in the levels of mutated Myoc
expression as well as by differences in genetic background
[103].
6. Conclusions
This paper describes animal models used in glaucoma
research. These animal models are essential to elucidate the
natural course of the disease and to develop novel thera-
peutic approaches. However, glaucoma is a disorder with
complicated pathogenesis that is far from being completely
understood. Since the mechanisms of glaucoma differ among
animal models, the selection of an animal model should be
based on experimental needs and the hypothesis being tested.
Experimentally, induced in vivo models have the advantage
of studying certain changes in glaucoma in a living animal.
However, the duration of IOP elevation in these models is
transient without sequential treatments. In addition, precise
control over IOP is difficult, and the timing of induction
and progression of glaucoma are often unpredictable. While
in vivo animal models are necessary to demonstrate that
a phenomenon occurs in living organisms, in vivo animal
experiments usually include undefined and uncontrollable
factors. For this reason, in vitro systems have been useful
for conducting highly controlled experiments in specific
contexts. In vitro experiments using primary cultures of
RGCs are not easy to perform, however, mainly because of
the limited cellular yield in adult animals and the typically
postmitotic feature of RGCs. Thus, early postnatal tissues
are used in order to optimize cell number and survival in
culture. It is important to note, however, that there are major
differences in cell responses to external stimulation between
postnatal and adult cells. In addition, it is difficult to examine
the interaction between RGCs and other types of cells such
as retinal glia under these conditions. Recently developed
ex vivo models for acute glaucoma involve incubating rat
retinal segments under hydrostatic pressure at the bottom
of a deep cylinder. The ex vivo hydrostatic pressure model
excludes the effects of ischemia and allows studying of the
direct effects of pressure on the retina. Additionally, this
model includes higher degrees of control over experimental
variables and better preservation of neuron-neuron and
neuron-glial interactions that are possible in dissociated cell
preparations. Ex vivo models are limited by the absence of
survival factors supplied by blood or axonal transport, and
the incubation period is time limited. Going forward, it is
likely that genetic models developed to test specific hypothe-
ses will provide valuable information on pathophysiology
and potentially lead to the discovery of new therapeutic
targets. By using these animal models, we hope to continue
to improve glaucoma prevention and treatment.
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